Back to News
Market Impact: 0.3
MHRA Approves Pharming Group N.V.’s Joenja as First Treatment Specifically for Children with APDS in the U.K.
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct LaunchesCompany Fundamentals
The U.K. MHRA approved an extension of Pharming Group’s Joenja marketing authorization to include children aged 4 to 11 years. The article text is truncated after mentioning a weight criterion, so no minimum or maximum weight is available.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.40
Ticker Sentiment
PHAR0.75
More News
- Tech stock rout, driven by US AI fears, continues in Asian trading
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- AI stocks hammered by midterm shock as data center buildout becomes a 'war of attrition'
- Fox completes its $22B acquisition of Roku
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- Paraguay’s Santiago Pena under arrest, new president Pedro Alliana sworn in